Drug Trial Radar · NCT01464190
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
Last checked: Nov 20, 2026Latest source record: Apr 1, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
659
Actual
Start
Sep 2011
Primary completion
Oct 2012
Study completion Apr 2013
Sponsor
- Lead sponsor
- Vifor PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Fresenius Medical Care North America
- First posted
- Nov 3, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. This is an extension study to PA-CL-05A (NCT01324128), subjects have already been enrolled and have been treated with study medication for at least 24 weeks.
Conditions
- Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
PA21 (2.5 g tablet containing 500 mg iron)Drug
Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
Sevelamer carbonateDrug
Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline and Levels at Each Time Point for Serum PhosphorusTime frame: Every 4 weeks from baseline to Week 28
- Change From Baseline and Levels at Each Time Point for Serum CalciumTime frame: Every 4 weeks from baseline to Week 28
- Change From Baseline and Levels at Each Time Point for Serum Intact Parathyroid Hormone (iPTH)Time frame: Every 4 weeks from baseline to Week 28
Locations
15 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
San Antonio, Texas
Medizinische Abteilung Nephrologie und Dialyse
Sankt Pölten, Austria
CHU Sart Tilman
Liège, Belgium
Clinical Hospital Center Rijeka
Rijeka, Croatia
Hospital with Polyclinic Novy Jicin
Nový Jičín, Czechia
KfH Nierenzentrum Berlin-Neukoelln
Berlin, Germany
Vidzemes Hospital
Valmiera, Latvia
JSC "Diaverum Clinics"
Klaipėda, Lithuania
Teaching Hospital no.1 of Medical University of Lodz
Lodz, Poland
Dialmed Clinic SRL
Sibiu, Romania
Kemerovo Regional hospital
Kemerovo, Russia
Zvezdara Clinical Medical Center
Belgrade, Serbia
St Augustines Hospital
Durban, South Africa
Mykolayiv Regional Hospital
Mykolayiv, Ukraine
Dorset County Hospital NHS Foundation Trust
Dorset, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.